Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with PIK3CA-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study.
- DOI
- 10.3390/cancers18030468
- Published
- 2026 Jan 30
- Container
- Cancers
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/cancers18030468,
title = {Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with PIK3CA-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study.},
author = {Loizidis S and Michaelides D and Marcou Y and Kakouri E and Konstantinou I and Constantinidou A and Theophanous-Kitiri S and Papageorgiou E and Michailidou K and Galazi M},
year = {2026},
journal = {Cancers},
doi = {10.3390/cancers18030468},
url = {https://doi.org/10.3390/cancers18030468}
}RIS
TY - JOUR TI - Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with PIK3CA-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study. AU - Loizidis S AU - Michaelides D AU - Marcou Y AU - Kakouri E AU - Konstantinou I AU - Constantinidou A AU - Theophanous-Kitiri S AU - Papageorgiou E AU - Michailidou K AU - Galazi M PY - 2026 JO - Cancers DO - 10.3390/cancers18030468 UR - https://doi.org/10.3390/cancers18030468 ER -
APA
S, L., D, M., Y, M., E, K., I, K., A, C., S, T., E, P., K, M., & M, G. (2026). Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with PIK3CA-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study.. Cancers. https://doi.org/10.3390/cancers18030468
Source records
- pubmed · retrieved 2026-09-26T12:15:48.411Z